Agios Pharmaceuticals (NASDAQ: AGIO) is one of 285 public companies in the “Bio Therapeutic Drugs” industry, but how does it weigh in compared to its rivals? We will compare Agios Pharmaceuticals to related businesses based on the strength of its risk, valuation, profitability, institutional ownership, dividends, earnings and analyst recommendations.

Earnings & Valuation

This table compares Agios Pharmaceuticals and its rivals gross revenue, earnings per share and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Agios Pharmaceuticals $69.89 million -$198.47 million -9.76
Agios Pharmaceuticals Competitors $284.30 million $34.29 million 142.58

Agios Pharmaceuticals’ rivals have higher revenue and earnings than Agios Pharmaceuticals. Agios Pharmaceuticals is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Risk and Volatility

Agios Pharmaceuticals has a beta of 1.84, indicating that its share price is 84% more volatile than the S&P 500. Comparatively, Agios Pharmaceuticals’ rivals have a beta of 5.80, indicating that their average share price is 480% more volatile than the S&P 500.

Profitability

This table compares Agios Pharmaceuticals and its rivals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Agios Pharmaceuticals -506.39% -69.64% -43.12%
Agios Pharmaceuticals Competitors -5,300.58% -432.11% -40.00%

Analyst Recommendations

This is a breakdown of current ratings and target prices for Agios Pharmaceuticals and its rivals, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Agios Pharmaceuticals 0 1 11 0 2.92
Agios Pharmaceuticals Competitors 839 3190 11555 230 2.71

Agios Pharmaceuticals presently has a consensus price target of $75.70, suggesting a potential upside of 23.75%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 44.01%. Given Agios Pharmaceuticals’ rivals higher probable upside, analysts clearly believe Agios Pharmaceuticals has less favorable growth aspects than its rivals.

Institutional & Insider Ownership

94.3% of Agios Pharmaceuticals shares are owned by institutional investors. Comparatively, 50.0% of shares of all “Bio Therapeutic Drugs” companies are owned by institutional investors. 5.4% of Agios Pharmaceuticals shares are owned by insiders. Comparatively, 17.1% of shares of all “Bio Therapeutic Drugs” companies are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Summary

Agios Pharmaceuticals rivals beat Agios Pharmaceuticals on 7 of the 12 factors compared.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company’s therapeutic areas of focus are cancer and rare genetic metabolic disorders, which are a group of over 600 rare genetic diseases caused by mutations, or defects, of single metabolic genes. The Company’s cancer product candidates are enasidenib and ivosidenib (AG-120), which target mutated isocitrate dehydrogenase 2 (IDH2) and isocitrate dehydrogenase 1 (IDH1), respectively, and AG-881, which targets both mutated IDH1 and mutated IDH2. These mutations are found in a range of hematological malignancies and solid tumors. The lead product candidate in its rare genetic metabolic disorder (RGD), programs, AG-348, targets pyruvate kinase-R for the treatment of pyruvate kinase deficiency. Pyruvate kinase deficiency is a rare disorder that often results in severe hemolytic anemia due to inherited mutations in the pyruvate kinase enzyme within red blood cells.

Receive News & Ratings for Agios Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agios Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.